Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
Abou-Alfa, G.K., Qin, S., Ryoo, B.-Y., Lu, S.-N., Yen, C.-J., Feng, Y.-H., Lim, H.Y., Izzo, F., Colombo, M., Sarker, D., Bolondi, L., Vaccaro, G., Harris, W.P., Chen, Z., Hubner, R.A., Meyer, T., Sun, W., Harding, J.J., Hollywood, E.M., Ma, J., Wan, P.J., Ly, M., Bomalaski, J., Johnston, A., Lin, C.-C., Chao, Y., Chen, L.-T.
Published in Annals of oncology (01.06.2018)
Published in Annals of oncology (01.06.2018)
Get full text
Journal Article
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
Lee, Michael S, Ryoo, Baek-Yeol, Hsu, Chih-Hung, Numata, Kazushi, Stein, Stacey, Verret, Wendy, Hack, Stephen P, Spahn, Jessica, Liu, Bo, Abdullah, Heba, Wang, Yulei, He, Aiwu Ruth, Lee, Kyung-Hun, Bang, Y-J, Bendell, J, Chao, Y, Chen, J-S, Chung, H C, Davis, S L, Dev, A, Gane, E, George, B, He, A R, Hochster, H, Hsu, C-H, Ikeda, M, Lee, J, Lee, M, Mahipal, A, Manji, G, Morimoto, M, Numata, K, Pishvaian, M, Qin, S, Ryan, D, Ryoo, B-Y, Sasahira, N, Stein, S, Strickler, J, Tebbutt, N
Published in The lancet oncology (01.06.2020)
Published in The lancet oncology (01.06.2020)
Get full text
Journal Article
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
Chen, L.-T., Martinelli, E., Cheng, A.-L., Pentheroudakis, G., Qin, S., Bhattacharyya, G.S., Ikeda, M., Lim, H.-Y., Ho, G.F., Choo, S.P., Ren, Z., Malhotra, H., Ueno, M., Ryoo, B.-Y., Kiang, T.C., Tai, D., Vogel, A., Cervantes, A., Lu, S.-N., Yen, C.-J., Huang, Y.-H., Chen, S.-C., Hsu, C., Shen, Y.-C., Tabernero, J., Yen, Y., Hsu, C.-H., Yoshino, T., Douillard, J.-Y.
Published in Annals of oncology (01.03.2020)
Published in Annals of oncology (01.03.2020)
Get full text
Journal Article
Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
Pishvaian, M.J., Lee, M.S., Ryoo, B.-Y., Stein, S., Lee, K.-H., Verret, W., Spahn, J., Shao, H., Liu, B., Iizuka, K., Hsu, C.-H.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group
Kim, T.M., Lee, S.-Y., Jeon, Y.K., Ryoo, B.-Y., Cho, G.J., Hong, Y.S., Kim, H.J., Kim, S.-Y., Kim, C.S., Kim, S., Kim, J.S., Sohn, S.K., Song, H.H., Lee, J.L., Kang, Y.K., Yim, C.Y., Lee, W.S., Yuh, Y.J., Kim, C.W., Heo, D.S.
Published in Annals of oncology (01.08.2008)
Published in Annals of oncology (01.08.2008)
Get full text
Journal Article
Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy
Kang, Y.-K., Ryu, M.-H., Park, S.H., Kim, J.G., Kim, J.W., Cho, S.-H., Park, Y.-I., Park, S.R., Rha, S.Y., Kang, M.J., Cho, J.Y., Kang, S.Y., Roh, S.Y., Ryoo, B.-Y., Nam, B.-H., Jo, Y.-W., Yoon, K.-E., Oh, S.C.
Published in Annals of oncology (01.05.2018)
Published in Annals of oncology (01.05.2018)
Get full text
Journal Article
Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors
Yoo, C., Ryu, M.-H., Na, Y.S., Ryoo, B.-Y., Park, S.R., Kang, Y.-K.
Published in Annals of oncology (01.11.2014)
Published in Annals of oncology (01.11.2014)
Get full text
Journal Article
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
Ryu, M.-H., Baba, E., Lee, K.H., Park, Y.I., Boku, N., Hyodo, I., Nam, B.-H., Esaki, T., Yoo, C., Ryoo, B.-Y., Song, E.-K., Cho, S.-H., Kang, W.K., Yang, S.H., Zang, D.Y., Shin, D.B., Park, S.R., Shinozaki, K., Takano, T., Kang, Y.-K.
Published in Annals of oncology (01.10.2015)
Published in Annals of oncology (01.10.2015)
Get full text
Journal Article
Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma
Lee, J., Suh, C., Kang, H. J., Ryoo, B.-Y., Huh, J., Ko, Y. H., Eom, H.-S., Kim, K., Park, K., Kim, W. S.
Published in Annals of oncology (01.12.2008)
Published in Annals of oncology (01.12.2008)
Get full text
Journal Article
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
YOON, D. H, RYU, M.-H, PARK, Y. S, LEE, H. J, LEE, C, RYOO, B.-Y, LEE, J.-L, CHANG, H.-M, KIM, T. W, KANG, Y.-K
Published in British journal of cancer (13.03.2012)
Published in British journal of cancer (13.03.2012)
Get full text
Journal Article
Atezolizumab + bevacizumab in hepatocellular carcinoma (HCC): Safety and clinical activity results from a phase Ib study
Lee, K.-H., Hsu, C.-H., Lee, M.S., Ryoo, B.-Y., Verret, W., He, A.R., Kwan, A., Liu, B., Iizuka, K., Stein, S.
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study
Jeong, H., Shin, J., Jeong, J.H., Kim, K.-p., Hong, S.-M., Kim, Y.-i., Ryu, J.-S., Ryoo, B.-Y., Yoo, C.
Published in ESMO open (01.06.2021)
Published in ESMO open (01.06.2021)
Get full text
Journal Article
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
KANG, Y.-K, YOO, C, RYU, M.-H, RYOO, B.-Y, LEE, J. J, TAN, E, PARK, I, PARK, J. H, CHOI, Y. J, JO, J, RYU, J.-S
Published in British journal of cancer (29.10.2013)
Published in British journal of cancer (29.10.2013)
Get full text
Journal Article
Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)
Ip, H.N.N., Hwang, I., Kang, J., Kim, K.-P., Jeong, J.H., Chang, H.-M., Ryoo, B.-Y., Yoo, C.
Published in Annals of oncology (01.11.2018)
Published in Annals of oncology (01.11.2018)
Get full text
Journal Article
Prognostic factors in patients with advanced biliary tract cancer (BTC) who showed durable disease control with first-line gemcitabine plus cisplatin (GemCis)
Hyung, J., Yoo, C., Kim, K.-P., Kim, B.J., Jeong, J.H., Chang, H.-M., Ryoo, B.-Y.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Efficacy and safety of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX (FFX) as first line chemotherapy for metastatic pancreatic cancer (mPC): Retrospective analysis
Lee, K., Hwang, I., Kang, J., Yoo, C., Kim, K.-P., Jeong, J.H., Chang, H.-M., Ryoo, B.-Y.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Evaluation of genetic alterations in biliary tract cancer using targeted exome sequencing
Chae, H., Yoo, C., Kim, D., Jung, J.H., Chang, H.-M., Ryoo, B.-Y., Kim, K.-P.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)
Hwang, I., Kang, J., Yoo, C., Jeong, J.H., Kim, K.-P., Chang, H.-M., Ryoo, B.-Y.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX
Hyung, J., Lee, H., Jin, H., Lee, S., Lee, H.J., Gong, G., Song, T.J., Lee, S.S., Hwang, D.W., Kim, S.C., Jeong, J.H., Ryoo, B.-Y., Kim, K., Yoo, C.
Published in ESMO open (01.06.2022)
Published in ESMO open (01.06.2022)
Get full text
Journal Article
Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Finn, R.S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H.-Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., Yau, T., Garrido, M., Chan, S.L., Knox, J., Daniele, B., Ebbinghaus, S.W., Chen, E., Siegel, A.B., Zhu, A.X., Cheng, A.-L.
Published in Annals of oncology (01.07.2019)
Published in Annals of oncology (01.07.2019)
Get full text
Journal Article